Loading
XNW27011 is an experimental antibody-drug conjugate from Astellas Pharma Global Development in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and ovarian cancer, aimed at Claudin 18.2.
XNW27011 is an antibody-drug conjugate developed by Astellas Pharma Global Development. Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). The sponsor states: XNW27011 is an antibody-drug conjugate targeting Claudin 18.2, a tight-junction transmembrane protein, carrying the topoisomerase I inhibitor payload YL0010014, given intravenously every three weeks. ClinicalTrials.gov describes the intervention as: Eligible patient(s) in each dose cohort will receive the assigned XNW27011 dose administration every 3 weeks (Q3W, cycle) until intolerable toxicity, progression of the disease without clinical benefit, or withdrawal of informed consent. An. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in pancreatic ductal adenocarcinoma, non-small-cell lung cancer, ovarian cancer, colorectal cancer and biliary tract cancer. The largest, NCT06792435, plans to enrol 240 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
XNW27011 is an antibody-drug conjugate targeting Claudin 18.2, a tight-junction transmembrane protein, carrying the topoisomerase I inhibitor payload YL0010014, given intravenously every three weeks. Connects to Claudin 18.2.
1.XNW27011's antibody arm binds Claudin 18.2 on the surface of the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"XNW27011" OR ABSTRACT:"XNW27011") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about XNW27011, not a curated reading list.
Shares Biliary tract cancer (cholangiocarcinoma), Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Claudin 18.2, Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Claudin 18.2, Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Astellas, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.